179 related articles for article (PubMed ID: 12909237)
1. Lymphocyte radiosensitivity correlated with pelvic radiotherapy morbidity.
Lee TK; Allison RR; O'Brien KF; Johnke RM; Christie KI; Naves JL; Kovacs CJ; Arastu H; Karlsson UL
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):222-9. PubMed ID: 12909237
[TBL] [Abstract][Full Text] [Related]
2. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
Schultheiss TE; Hanks GE; Hunt MA; Lee WR
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):643-9. PubMed ID: 7790250
[TBL] [Abstract][Full Text] [Related]
3. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.
Liu M; Pickles T; Agranovich A; Berthelet E; Duncan G; Keyes M; Kwan W; McKenzie M; Morris J; Pai H; Tyldesley S; Wu J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):59-67. PubMed ID: 14697421
[TBL] [Abstract][Full Text] [Related]
4. Micronuclei in lymphocytes of prostate cancer patients undergoing radiation therapy.
Lee TK; O'Brien KF; Naves JL; Christie KI; Arastu HH; Eaves GS; Wiley AL; Karlsson UL; Salehpour MR
Mutat Res; 2000 Aug; 469(1):63-70. PubMed ID: 10946243
[TBL] [Abstract][Full Text] [Related]
5. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
6. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
[TBL] [Abstract][Full Text] [Related]
7. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
[TBL] [Abstract][Full Text] [Related]
8. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
9. Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis.
Jani AB; Hand CM; Pelizzari CA; Roeske JC; Krauz L; Vijayakumar S
BMC Cancer; 2003 May; 3():16. PubMed ID: 12744725
[TBL] [Abstract][Full Text] [Related]
10. Late GI and GU complications in the treatment of prostate cancer.
Schultheiss TE; Lee WR; Hunt MA; Hanlon AL; Peter RS; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):3-11. PubMed ID: 9054871
[TBL] [Abstract][Full Text] [Related]
11. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
Choo R; Pearse M; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):989-95. PubMed ID: 18436391
[TBL] [Abstract][Full Text] [Related]
12. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
13. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
Kalakota K; Liauw SL
Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
[TBL] [Abstract][Full Text] [Related]
14. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique.
Su AW; Jani AB
Am J Clin Oncol; 2007 Jun; 30(3):215-9. PubMed ID: 17551295
[TBL] [Abstract][Full Text] [Related]
15. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
16. Image-guided radiation therapy based on helical tomotherapy in prostate cancer: minimizing toxicity.
Acevedo-Henao CM; Lopez Guerra JL; Matute R; Puebla F; Russo M; Rivin E; Sanchez-Reyes A; Ortiz MJ; Azinovic I
Oncol Res Treat; 2014; 37(6):324-30. PubMed ID: 24903763
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
Feng M; Hanlon AL; Pisansky TM; Kuban D; Catton CN; Michalski JM; Zelefsky MJ; Kupelian PA; Pollack A; Kestin LL; Valicenti RK; DeWeese TL; Sandler HM
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1417-23. PubMed ID: 17418972
[TBL] [Abstract][Full Text] [Related]
19. Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer.
Barber JB; Burrill W; Spreadborough AR; Levine E; Warren C; Kiltie AE; Roberts SA; Scott D
Radiother Oncol; 2000 May; 55(2):179-86. PubMed ID: 10799730
[TBL] [Abstract][Full Text] [Related]
20. Persistence of micronuclei in lymphocytes of cancer patients after radiotherapy.
Lee TK; Allison RR; O'Brien KF; Naves JL; Karlsson UL; Wiley AL
Radiat Res; 2002 Jun; 157(6):678-84. PubMed ID: 12005547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
